Piperazine-substituted pyrroloanthracene as immuno-moderators

Piperazine-substituted pyrroloanthracenes of general formula (I) in which E and L together form a heterocyclic radical of formula (A) are produced if either furanoanthracene is reacted with piperazine alkyl amines or unsbustituted pyrolloanthracene is first reacted with dihalogen alkyl compounds and then with corespondingly substituted piperazines or if furane derivatives are first reacted with piperazine alkyl amines and then condensed with anthracenes. The novel compounds can be used as active agents in medicaments, especially in immuno-modulators.